Three-year supply contract: Lunit INSIGHT CXR and Lunit INSIGHT CXR Triage to enhance lung abnormality detection in Samsung's premium X-ray devices
SEOUL, South Korea, January 16, 2024 -- ▲ Lunit's AI-powered chest X-ray analysis solution 'Lunit INSIGHT CXR'

Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced a three-year supply contract with Samsung Electronics (Samsung Healthcare). The collaboration centers around the integration of Lunit's AI technology into Samsung's premium X-ray devices, elevating the accuracy and speed of chest screening.
Under the terms of the contract, Lunit will supply Samsung Electronics with two AI-powered chest screening solutions: Lunit INSIGHT CXR and Lunit INSIGHT CXR Triage. The initial phase of this collaboration will see the X-ray devices, enhanced with Lunit's AI solutions, targeting the markets in the US, Canada, and Europe. Future phases aim to expand this to the Middle East, South America, and Southeast Asia, thereby broadening the global reach.
At a glance
- Company
- Lunit
- Ticker
- KRX: 328130.KQ
- Announcement
- Partnership
- Location
- Seoul, South Korea
Key figures
- Supply contract term
- three-year
- Common lung abnormalities INSIGHT CXR detects
- 10
People
- Brandon SuhCEO of Lunit
Products and programs
In line with the urgency of cases typically encountered in Intensive Care Units (ICUs) and Emergency Rooms (ERs), X-ray devices with the Lunit INSIGHT CXR Triage are expected to be primarily deployed in these high-stakes medical settings.
"The synergy between Lunit and Samsung Electronics will enable faster, more accurate chest screenings, leading to timely interventions and improved patient outcomes. We’re excited about the potential this partnership holds for advancing chest X-ray practices, particularly in ICUs and ERs,” said Brandon Suh, CEO of Lunit.
Lunit INSIGHT CXR, an AI-powered chest X-ray analysis solution, stands out for its capability to detect 10 of the most common lung abnormalities, including lung cancer, pneumonia, and pneumothorax. Lunit INSIGHT CXR Triage is an FDA-cleared AI solution that identifies pre-specified critical findings, such as pleural effusion or pneumothorax, on frontal chest X-ray images. The software then flags the images in the Picture Archiving and Communication System (PACS)/workstation, enabling a prioritized review process for timely intervention.
If you detect any issues, problems, or errors in this press release content, kindly contact [email protected] to notify us (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). We will respond and rectify the situation in the next 8 hours.
In brief
Lunit says it has signed a three-year supply contract with Samsung Electronics’ Samsung Healthcare business to provide two AI chest X-ray solutions for integration into Samsung’s premium X-ray devices. The products, Lunit INSIGHT CXR and Lunit INSIGHT CXR Triage, are intended to support detection and prioritization of chest findings. The initial rollout is planned for the United States, Canada and Europe, with later phases intended to extend to the Middle East, South America and Southeast Asia. Lunit says the triage solution is expected to be used mainly in intensive care units and emergency rooms. The company describes INSIGHT CXR as detecting 10 common lung abnormalities, while INSIGHT CXR Triage identifies specified critical findings and flags images in a PACS or workstation for prioritized review.
Key takeaways
- Lunit will supply two AI chest X-ray solutions under a three-year contract with Samsung Electronics.
- The initial target markets are the United States, Canada and Europe.
- Lunit says the triage software flags specified findings to support prioritized image review.
- The company says INSIGHT CXR can detect 10 common lung abnormalities.
Earlier from Lunit
- Lunit to Acquire Volpara: Scheme Implementation Agreement Signed
- Lunit Advances to Stage 2 of Australia's National Breast Cancer Screening Project
- Lunit to Advance Singapore’s Healthcare Landscape with AI-powered Chest Screening Solution Integrated into National AI Platform
- AI-Powered TIL Analysis by Lunit Unveils Prognostic Insights for Colon Cancer - published in npj Precision Oncology
- Lunit's AI-Powered Mammography Analysis Solution Proves Comparable to Radiologists in Breast Cancer Detection - published in European Radiology